MacroGenics, Inc. is a biopharmaceutical company, which engages in the development and commercialization of antibody-based therapeutics for the treatment of cancer. Its product pipeline includes Margetuximab, Flotetuzumab, Retifanlimab, Enoblituzumab, Tebotelimab, MGC018, MGD019, IMGC936, and MGD014 for infectious diseases. The company was founded by Scott E. Koenig, Jeffrey V. Ravetch, LeRoy E. Hood, Ruedi Aebersold, and Alan Aderem on August 14, 2000 and is headquartered in Rockville, MD.
Sector:
Health Technology
Industry:
Pharmaceuticals Major
Employees:
293
Frequently Asked Questions
Market cap, also known as market capitalization, is the total market value of a company. It's calculated by multiplying the current market price by the total number of shares outstanding. Macrogenics Inc market cap is $140.6M.
52 week high is the highest price of a stock in the past 52 weeks, or one year. Macrogenics Inc 52 week high is $5.08 as of November 17, 2026.
52 week low is the lowest price of a stock in the past 52 weeks, or one year. Macrogenics Inc 52 week low is $1.32 as of November 17, 2026.
Macrogenics Inc stock price today is $2.17.
Macrogenics Inc stock price yesterday was $2.20.
The Price-to-Earnings (or P/E) ratio is a commonly used tool for valuing a company. It's calculated by dividing the current share price by the earnings per share (or EPS). It can also be calculated by dividing the company's Market Cap by the Net Profit. Macrogenics Inc's P/E ratio is -2.6.
The Price-to-Book (P/B) ratio is a commonly used tool for valuing a company. It's calculated by dividing a company's market capitalization by its book value. Macrogenics Inc P/B ratio is 5.5111.
The 50-day moving average is a frequently used data point by active investors and traders to understand the trend of a stock. It's calculated by averaging the closing stock price over the previous 50 trading days. Macrogenics Inc 50-day moving average is $3.28.